NoNO-42

DRUG3 trials

Sponsors

NoNO Inc., The George Institute

Conditions

Acute Ischemic StrokeFirst-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic StrokeStroke

Phase 1

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

CompletedNCT05636306

NoNO Inc.First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke

Start: 2022-11-22End: 2023-10-05Updated: 2024-05-16

Phase 2

NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy

RecruitingNCT06403267

NoNO Inc.Acute Ischemic Stroke

Start: 2024-10-02End: 2026-12-31Target: 600Updated: 2025-07-15

Phase 3

ACT-GLOBAL Adaptive Platform Trial for Stroke

RecruitingNCT06352632

The George InstituteStroke

Start: 2024-09-26End: 2034-09-01Target: 20000Updated: 2026-07-08